HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Lowers Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on BridgeBio Pharma (NASDAQ:BBIO) but lowered the price target from $47 to $43.
May 20, 2024 | 10:24 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on BridgeBio Pharma but lowered the price target from $47 to $43.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100